PancytopeniaNCT05473650
Spectrum of Hematological Disorders in Pediatrics
An observational study of Pancytopenia, run by Assiut University.
Trial summary
To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year Read more about this study
- Who is it for?
- Ages 28 days to 18 years
- Conditions the study is for
- Pancytopenia
- What is being tested?
- CBC.with with differential Peripheral smear
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2022to 1 Nov 2023
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 28 days to 18 years
- All sexes
- Child, Adult
Study population: patients with pancytopenia from the age of one month to 18 years old
Who may be able to join
- All patients with presistant pancytopenia from age 1 month to 18 years at Assiut university hospital of pediatrics
Who cannot join
- Patients below age of 1 month or above 18 years
Trial locations and contacts
No sites are listed yet.
About this study
Official title: A Spectrum of Hematological Disorders in Children Presented With Pancytopenia at Assiut University Hospital
To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year
Read the detailed description
Pancytopenia is a condition in which there is a decrease of all the three cellular elements of blood, namely erythrocytes, leukocytes, and platelets . It is quite a common finding among children. According to regional studies, it makes up around 2.90% to 3.57% of the burden of presentations in the pediatric population. Some of the presenting symptoms include, but are not limited to, pallor, fever, weight loss, dyspnea, bleeding, bruising, visceromegaly, and increased risk of infections .
Pancytopenia is not a disease in itself but a laboratory finding of the constitution of diseases. It can occur due to a variety of disorders which can be as simple as nutritional deficiencies to serious malignant disorders . Megaloblastic anemia and acute lymphoblastic leukemia are among the most common presentations of pancytopenia.
Pancytopenia results in a hypoplastic bone marrow. It is diagnosed on the basis of the complete blood count test. Pancytopenia is labeled when the hemoglobin (hb) is less than 10 gm%, absolute neutrophil count (anc) is less than 1.5*109/l, and platelet count is less than 100*109/l [9].
But, in order to find out the etiological factor causing pancytopenia, bone marrowexamination is done. Being an interventional procedure, it is relatively safe with little or no risk of bleeding.
Etiology of pancytopenia The etiology of pancytopenia can be broadly categorized as a central type that involves disorders of production or a peripheral type that involves disorders of increased destruction.These causes could contribute to the pancytopenia independently or as a combination.
Decreased production (central type): Pancytopenia due to decreased production is mostly secondary to nutritional deficiencies. Pancytopenia caused by bone marrow failure is known as aplastic anemia. Aplastic anemia could be idiopathic/autoimmune, secondary to infections (such as parvovirus B19, hepatitis, human immunodeficiency virus (HIV), cytomegalovirus, or Epstein-Barr virus), after drug toxicity, or chemotherapeutic agents (methotrexate, dapsone, carbimazole, carbamazepine, chloramphenicol). Pancytopenia can also be related to inadequate intake (as seen in eating disorders and alcoholics) or malabsorption.The production of cell lines is also impaired when the bone marrow is infiltrated by malignancies (lymphoma, leukemia, multiple myeloma) or granulomatous disorders. Metastatic tumors can also cause bone marrow replacement late in the disease, thus producing pancytopenia.
Increased destruction (peripheral type): Peripheral destruction of cells can be associated with many autoimmune conditions (such as systemic lupus erythematosus, rheumatoid arthritis) and splenic sequestration (alcoholic liver cirrhosis, HIV, tuberculosis, malaria). Hypersplenism affects more frequently the platelets and erythrocytes than leukocytes.
Differential diagnosis Multiple conditions can present with pancytopenia; hence, when someone shows with pancytopenia, a complete evaluation is performed to detect the cause of pancytopenia. Bone marrow disorders such as aplastic anemia, myelodysplastic syndrome, acute leukemia, myelofibrosis, megaloblastic anemia, paroxysmal nocturnal hemoglobinuria, and Fanconi's anemia can present with pancytopenia. Fanconi anemia is the most common congenital cause of bone marrow failure with an autosomal recessive inheritance pattern. In myelofibrosis, there is a replacement of the bone marrow cells with fibrotic tissue. Malignancies such as lymphoma, multiple myeloma, and hairy cell leukemia can also present with pancytopenia. Non-bone marrow conditions present with pancytopenia include systemic lupus erythematosus, infections (such as parvovirus B19, Epstein Barr virus, HIV, hepatitis, leishmaniasis, tuberculosis, malaria, and histoplasmosis).
- Conditions
- Pancytopenia
- Being tested
- CBC.with with differential Peripheral smear
- Medical subject headings
- Pancytopenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CBC.with with differential Peripheral smearDiagnostic test
determine spectrum of hematological disorders in childern with pancytopenia
What is being measured
The primary outcome is the main question the study is designed to answer.
percentage of aplastic anemia among other causes of pancytopenia in childern presented to assiut university childern hospital with abnormal CBC
getting a proper diagnosis of different cases of pancytopeina in childern which helps in their treatment
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Jul 2022
- Study start1 Sep 2022 (estimated)
- Primary completion30 Sep 2023 (estimated)
- Study completion1 Nov 2023 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (7)Papers the sponsor has linked to this study.
- Other trials for PancytopeniaStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Zakria Younes Mohammed Essemy, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05473650
- Sponsor's protocol ID
- pancytopenia in pediatrics
- Status last verified
- Jul 2022
- First submitted
- 19 Jul 2022
- Last updated
- 26 Jul 2022
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Memon S, Shaikh S, Nizamani MA. Etiological spectrum of pancytopenia based on bone marrow examination in children. J Coll Physicians Surg Pak. 2008 Mar;18(3):163-7.
PubMed 18460245Sharma R, Nalepa G. Evaluation and Management of Chronic Pancytopenia. Pediatr Rev. 2016 Mar;37(3):101-111; quiz 112-3. doi: 10.1542/pir.2014-0087. No abstract available.
PubMed 26933225Das Makheja K, Kumar Maheshwari B, Arain S, Kumar S, Kumari S, Vikash. The common causes leading to pancytopenia in patients presenting to tertiary care hospital. Pak J Med Sci. 2013 Sep;29(5):1108-11. doi: 10.12669/pjms.295.3458.
PubMed 24353701Zeb Jan A, Zahid B, Ahmad S, Gul Z. Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman Medical Institute, Peshawar. Pak J Med Sci. 2013 Sep;29(5):1153-7. doi: 10.12669/pjms.295.3865.
PubMed 24353710Jain A, Naniwadekar M. An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital. BMC Hematol. 2013 Nov 6;13(1):10. doi: 10.1186/2052-1839-13-10.
PubMed 24238033Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK. Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Rev. 2018 Sep;32(5):361-367. doi: 10.1016/j.blre.2018.03.001. Epub 2018 Mar 5.
PubMed 29555368Takeshima M, Ishikawa H, Kitadate A, Sasaki R, Kobayashi T, Nanjyo H, Kanbayashi T, Shimizu T. Anorexia nervosa-associated pancytopenia mimicking idiopathic aplastic anemia: a case report. BMC Psychiatry. 2018 May 25;18(1):150. doi: 10.1186/s12888-018-1743-6.
PubMed 29801443
Study at a glance
From the registry record, last updated by the sponsor on 26 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Spectrum of Hematological Disorders in Children Presented With Pancytopenia at Assiut University Hospital
- ClinicalTrials.gov ID
- NCT05473650
- Acronym / sponsor ID
- pancytopenia in pediatrics
- Conditions
- Pancytopenia
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Sep 2022 (estimated)
- Primary completion
- 30 Sep 2023 (estimated)
- Study completion
- 1 Nov 2023 (estimated)
- First posted
- 26 Jul 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine the spectrum of pancytopenia with its frequency and etiology in children presenting to Assiut University Children Hospital during one year
Detailed description
Pancytopenia is a condition in which there is a decrease of all the three cellular elements of blood, namely erythrocytes, leukocytes, and platelets . It is quite a common finding among children. According to regional studies, it makes up around 2.90% to 3.57% of the burden of presentations in the pediatric population. Some of the presenting symptoms include, but are not limited to, pallor, fever, weight loss, dyspnea, bleeding, bruising, visceromegaly, and increased risk of infections .
Pancytopenia is not a disease in itself but a laboratory finding of the constitution of diseases. It can occur due to a variety of disorders which can be as simple as nutritional deficiencies to serious malignant disorders . Megaloblastic anemia and acute lymphoblastic leukemia are among the most common presentations of pancytopenia.
Pancytopenia results in a hypoplastic bone marrow. It is diagnosed on the basis of the complete blood count test. Pancytopenia is labeled when the hemoglobin (hb) is less than 10 gm%, absolute neutrophil count (anc) is less than 1.5*109/l, and platelet count is less than 100*109/l [9].
But, in order to find out the etiological factor causing pancytopenia, bone marrowexamination is done. Being an interventional procedure, it is relatively safe with little or no risk of bleeding.
Etiology of pancytopenia The etiology of pancytopenia can be broadly categorized as a central type that involves disorders of production or a peripheral type that involves disorders of increased destruction.These causes could contribute to the pancytopenia independently or as a combination.
Decreased production (central type): Pancytopenia due to decreased production is mostly secondary to nutritional deficiencies. Pancytopenia caused by bone marrow failure is known as aplastic anemia. Aplastic anemia could be idiopathic/autoimmune, secondary to infections (such as parvovirus B19, hepatitis, human immunodeficiency virus (HIV), cytomegalovirus, or Epstein-Barr virus), after drug toxicity, or chemotherapeutic agents (methotrexate, dapsone, carbimazole, carbamazepine, chloramphenicol). Pancytopenia can also be related to inadequate intake (as seen in eating disorders and alcoholics) or malabsorption.The production of cell lines is also impaired when the bone marrow is infiltrated by malignancies (lymphoma, leukemia, multiple myeloma) or granulomatous disorders. Metastatic tumors can also cause bone marrow replacement late in the disease, thus producing pancytopenia.
Increased destruction (peripheral type): Peripheral destruction of cells can be associated with many autoimmune conditions (such as systemic lupus erythematosus, rheumatoid arthritis) and splenic sequestration (alcoholic liver cirrhosis, HIV, tuberculosis, malaria). Hypersplenism affects more frequently the platelets and erythrocytes than leukocytes.
Differential diagnosis Multiple conditions can present with pancytopenia; hence, when someone shows with pancytopenia, a complete evaluation is performed to detect the cause of pancytopenia. Bone marrow disorders such as aplastic anemia, myelodysplastic syndrome, acute leukemia, myelofibrosis, megaloblastic anemia, paroxysmal nocturnal hemoglobinuria, and Fanconi's anemia can present with pancytopenia. Fanconi anemia is the most common congenital cause of bone marrow failure with an autosomal recessive inheritance pattern. In myelofibrosis, there is a replacement of the bone marrow cells with fibrotic tissue. Malignancies such as lymphoma, multiple myeloma, and hairy cell leukemia can also present with pancytopenia. Non-bone marrow conditions present with pancytopenia include systemic lupus erythematosus, infections (such as parvovirus B19, Epstein Barr virus, HIV, hepatitis, leishmaniasis, tuberculosis, malaria, and histoplasmosis).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 28 days to 18 years
- Sex
- All
- Age groups
- Child, Adult
- Study population
- patients with pancytopenia from the age of one month to 18 years old
Key inclusion criteria (1 listed)
- All patients with presistant pancytopenia from age 1 month to 18 years at Assiut university hospital of pediatrics
Key exclusion criteria (1 listed)
- Patients below age of 1 month or above 18 years
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CBC.with with differential Peripheral smeardetermine spectrum of hematological disorders in childern with pancytopenia | Diagnostic test | – |
Primary outcome
percentage of aplastic anemia among other causes of pancytopenia in childern presented to assiut university childern hospital with abnormal CBC
Time frame: one year
getting a proper diagnosis of different cases of pancytopeina in childern which helps in their treatment
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 26 Jul 2022.
- Background: PubMed 18460245Memon S, Shaikh S, Nizamani MA. Etiological spectrum of pancytopenia based on bone marrow examination in children. J Coll Physicians Surg Pak. 2008 Mar;18(3):163-7.
- Background: PubMed 26933225Sharma R, Nalepa G. Evaluation and Management of Chronic Pancytopenia. Pediatr Rev. 2016 Mar;37(3):101-111; quiz 112-3. doi: 10.1542/pir.2014-0087. No abstract available.
- Background: PubMed 24353701Das Makheja K, Kumar Maheshwari B, Arain S, Kumar S, Kumari S, Vikash. The common causes leading to pancytopenia in patients presenting to tertiary care hospital. Pak J Med Sci. 2013 Sep;29(5):1108-11. doi: 10.12669/pjms.295.3458.
- Background: PubMed 24353710Zeb Jan A, Zahid B, Ahmad S, Gul Z. Pancytopenia in children: A 6-year spectrum of patients admitted to Pediatric Department of Rehman Medical Institute, Peshawar. Pak J Med Sci. 2013 Sep;29(5):1153-7. doi: 10.12669/pjms.295.3865.
- Background: PubMed 24238033Jain A, Naniwadekar M. An etiological reappraisal of pancytopenia - largest series reported to date from a single tertiary care teaching hospital. BMC Hematol. 2013 Nov 6;13(1):10. doi: 10.1186/2052-1839-13-10.
- Background: PubMed 29555368Gnanaraj J, Parnes A, Francis CW, Go RS, Takemoto CM, Hashmi SK. Approach to pancytopenia: Diagnostic algorithm for clinical hematologists. Blood Rev. 2018 Sep;32(5):361-367. doi: 10.1016/j.blre.2018.03.001. Epub 2018 Mar 5.
- Background: PubMed 29801443Takeshima M, Ishikawa H, Kitadate A, Sasaki R, Kobayashi T, Nanjyo H, Kanbayashi T, Shimizu T. Anorexia nervosa-associated pancytopenia mimicking idiopathic aplastic anemia: a case report. BMC Psychiatry. 2018 May 25;18(1):150. doi: 10.1186/s12888-018-1743-6.
Related trials for Pancytopenia
RecruitingPhase 1/2
The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia
Aplastic Anemia, Refractory
RecruitingPhase 1/2
Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms
Myelodysplastic Syndromes
RecruitingObservational study
Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia
Fanconi Anemia, Inherited Bone Marrow Failure Syndrome
Not yet recruitingObservational study
Clinical Genetics Branch Eligibility Screening Survey
Melanoma, Li-Fraumeni Syndrome
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
An observational study of Pancytopenia, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 26 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact zakria younes mohammed, resident doctor (01121224119, zakriaessemy@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
percentage of aplastic anemia among other causes of pancytopenia in childern presented to assiut university childern hospital with abnormal CBC (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05473650, which also lists 7 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jul 2022.